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Asthma is a very common condition affecting 5.4 million
people in the United Kingdom. Daily use of inhaled corti-
costeroids (ICS) prevents acute exacerbations and reduces
need of other inhalers (ie Salbutamol). They are however
amongst the most expensive prescription medicines in the
UK, bearing a substantial financial burden on the NHS.
ICS use is also linked with a higher risk of side effects
such as developing oral thrush.
Guidelines published by NICE stress that apt patient
education is one necessary component of managing
asthma, to increase adherence to treatment and subse-
quently improve symptomatic control. To assess the degree
of adherence to ICS treatment, the files of all asthmatic
patients currently prescribed ICS were analyzed, focusing
on regularity of dispensing medicines.
The results showed that the vast majority of patients
were using their ICS inhaler in an ad-hoc fashion and not
as prescribed; concluding that these patients did not
require their ICS inhalers (either entirely, or at their cur-
rent dosages). A significant cause of this was identified as
being a lack of, or poor use of, communication between
the practitioner and patient at the time of prescribing.
In conclusion, insufficient patient education at time of
starting medicines leads to poor adherence to treatment
and causes financial inefficiencies regarding prescribing,
for any given practice. Patient understanding must
always be gauged, at the time of starting ICS treatment,
and thereon, during subsequent consultations. To aid
this process, a patient information leaflet should be used
as means of signposting for the practitioner and as a
treatment record for the patient.
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